Literature DB >> 11502549

Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal.

P C Fuchs1, A L Barry, S D Brown.   

Abstract

Quinupristin-dalfopristin (Q-D) and eight other antimicrobial agents were tested alone and in combination with Q-D in time-kill studies against 10 strains of macrolide-lincosamide-streptogramin B-resistant Staphylococcus aureus. Although Q-D is normally a bactericidal drug, it was only bacteriostatic for these isolates. Gentamicin alone was bactericidal against 7 of the 10 strains, and Q-D did not alter that killing effect. However, when vancomycin, cefepime, ceftazidime, imipenem, piperacillin-tazobactam, and ciprofloxacin were bactericidal when tested alone, the killing rates were reduced when combined with Q-D. The clinical significance of this in vitro antagonism is unknown at this time, and more studies are needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502549      PMCID: PMC90712          DOI: 10.1128/AAC.45.9.2662-2665.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci.

Authors:  J C Pechère
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

3.  In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci.

Authors:  R Auckenthaler; P Courvalin; C Féger; G Roche
Journal:  Clin Microbiol Infect       Date:  2000-11       Impact factor: 8.067

4.  RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci.

Authors:  G L Archer; P Auger; G V Doern; M J Ferraro; P C Fuchs; J H Jorgensen; D E Low; P R Murray; L B Reller; C W Stratton
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Mar-Apr       Impact factor: 2.803

5.  Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics.

Authors:  J Vouillamoz; J M Entenza; C Féger; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

6.  In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.

Authors:  W Brumfitt; J M Hamilton-Miller; S Shah
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

7.  Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

Authors:  R Leclercq; L Nantas; C J Soussy; J Duval
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

8.  Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

Authors:  B Fantin; R Leclercq; Y Merlé; L Saint-Julien; C Veyrat; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

Authors:  R N Jones; C H Ballow; D J Biedenbach; J A Deinhart; J J Schentag
Journal:  Diagn Microbiol Infect Dis       Date:  1998-07       Impact factor: 2.803

10.  Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.

Authors:  J M Entenza; H Drugeon; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  2 in total

1.  Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Fiorenza Orlando; Federico Mocchegiani; Alessandra Riva; Maria Simona Del Prete; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics.

Authors:  Juliette Pavie; Agnès Lefort; Virginie Zarrouk; Françoise Chau; Louis Garry; Roland Leclercq; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.